Patents Assigned to INCYTE Pharamaceuticals, Inc.
  • Human vesicle binding protein
    Patent number: 6054290
    Abstract: The present invention provides a human vesicle binding protein (MVBP) and polynucleotides which identify and encode MVBP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing MVBP and for treating or preventing disorders associated with expression of MVBP.
    Type: Grant
    Filed: May 15, 1997
    Date of Patent: April 25, 2000
    Assignee: Incyte Pharamaceuticals, Inc.
    Inventors: Olga Bandman, Phillip R. Hawkins, Lynn E. Murry
  • Human keratins
    Patent number: 5994081
    Abstract: The invention provides human keratins (KERT) and polynucleotides which identify and encode KERT. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of KERT.
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: November 30, 1999
    Assignee: Incyte Pharamaceuticals, Inc.
    Inventors: Y. Tom Tang, Jennifer L. Hillman, Neil C. Corley, Mariah Baughn
  • Protease nexin-I variants
    Patent number: 5457090
    Abstract: One or more amino acid residues within the reactive site region of protease nexin-I are altered in order to create analogs or variants of protease nexin-I. These analogs have substantially different protease specificities as well as different effects on regulating the activity of proteolytic enzymes which enzymes have substantial effects on a number of different physiological functions. Formulations containing the protease nexin-I variants and methods for administering these formulations to obtain desirable therapeutic results are disclosed.
    Type: Grant
    Filed: August 3, 1992
    Date of Patent: October 10, 1995
    Assignee: Incyte Pharamaceuticals, Inc.
    Inventors: Randy W. Scott, Fred Golini, Michael McGrogan
  • Recombinant, non-glycosylated bpi protein and uses thereof
    Patent number: 5334584
    Abstract: The present invention provides a method for preventing endotoxin-associated shock in a subject which comprises administering to the subject an amount of a BPI protein effective to bind to endotoxin so as to prevent endotoxin associated shock in the subject. This invention further provides a method for treating a subject suffering from endotoxin-associated shock which comprises administering to the subject an amount of a BPI protein effective to bind endotoxin so as to treat the subject suffering from endotoxin-associated shock.
    Type: Grant
    Filed: December 14, 1992
    Date of Patent: August 2, 1994
    Assignee: INCYTE Pharamaceuticals, Inc.
    Inventors: Randal W. Scott, Marian N. Marra